GABAB PAM for CMT1A, chronic cough and pain.

Our license agreement with Indivior provides for a funded research program, under which we have the right to select drug candidates for exclusive development in certain indications outside of SUD.

We plan to develop our selected drug candidates in CMT1a, chronic cough and pain. These indications have been validated with baclofen, an orthosteric agonist of GABAB and present a significant unmet medical need and commercial opportunity.

We are in clinical candidate selection phase and expect IND enabling studies to be initiated in 2024.